|Trade names||Lorcet, Norco, Vicodin, others|
|Other names||Hydrocodone/acetaminophen, hydrocodone/APAP|
|AHFS/Drugs.com||Professional Drug Facts|
|Metabolism||Hydrocodone: extensively liver, primarily CYP3A4;|
/Paracetamol: liver, CYP2E1
|Elimination half-life||for hydrocodone: 228–294 mins (3.8–4.9 hrs); for paracetamol: 120–240 mins (2–4 hrs)|
|Excretion||for hydrocodone: urinary; for paracetamol: urinary (10–15% unchanged)|
|(what is this?)|
Hydrocodone/paracetamol (also known as hydrocodone/acetaminophen) is the combination of the pain medications hydrocodone and paracetamol (acetaminophen). It is used to treat moderate to severe pain. It is taken orally.  Recreational use is common in the United States.
Common side effects include dizziness, sleepiness, constipation, and vomiting. Serious side effects include addiction, decreased rate of breathing, low blood pressure, serotonin syndrome, severe allergic reactions, and liver failure. Use during pregnancy may harm the baby. Use with alcohol is not recommended. Hydrocodone works by binding to the mu-opioid receptor. How paracetamol works is unclear but may involve blocking the creation of prostaglandins.
Hydrocodone/paracetamol was approved for medical use in the United States in 1982. In the United States, it is a schedule II controlled substance. In 2019, it was the fifteenth most commonly prescribed medication in the United States, with more than 30 million prescriptions. It is not available in the United Kingdom, though the combination codeine/paracetamol is. It is sold under the brand names Vicodin and Norco among others.
Hydrocodone/paracetamol is a fixed-dose combination consisting of the opioid hydrocodone and the non-opioid analgesic paracetamol. It is indicated for relief of moderate to severe pain of acute, chronic, or postoperative types. Hydrocodone/paracetamol comes in oral solution and tablet formulations; however strength of each component may vary. In October 2014, the Drug Enforcement Administration rescheduled hydrocodone combination drugs from schedule III to schedule II due to its risk for misuse, abuse, and diversions.
Hydrocodone diversion and recreational use has escalated in recent years due to its opioid effects. In 2009 and 2010, hydrocodone was the second most frequently encountered opioid pharmaceutical in drug evidence submitted to U.S. federal, state, and local forensic laboratories as reported by DEA's National Forensic Laboratory Information System (NFLIS) and System to Retrieve Information from Drug Evidence (STRIDE).
Pregnancy and breastfeeding
Pregnancy category C: Risk in pregnancy cannot be ruled out. Animal controlled studies have not been conducted with this medication.
Low concentrations of paracetamol is excreted through breast milk, however, hydrocodone's excretion is unknown.
Kidney and liver impairment
Use with caution due to possible risk of toxicity.
- Euphoria
- Nausea and vomiting
- Central nervous system: drowsiness, confusion, lethargy, anxiety, fear, unease, dependence, mood changes, impairment of mental and physical performance
- Gastrointestinal system: constipation
- Genitourinary system: inability to urinate, bladder spasms
- Respiratory depression: decreased rate and effort of breathing
- Hearing impairment, permanent hearing loss
- Dermatological: rash, itching
Black box warning
"Paracetamol has been associated with cases of acute liver failure, at times resulting in liver transplant or death. Most of the cases of liver injury are associated with the use of paracetamol at doses that exceed 4000 milligrams per day, and often involve more than one paracetamol-containing product."
"Do not take hydrocodone bitartrate and paracetamol tablets if you are allergic to any of its ingredients. If you develop signs of allergy such as a rash or difficulty breathing stop taking hydrocodone bitartrate and paracetamol tablets and contact your healthcare provider immediately."
Hydrocodone: Respiratory depression, extreme somnolence progressing towards coma, muscle limpness, cold and clammy skin, slow heart rate, low blood pressure, abrupt loss of heart function, and death may occur.
Paracetamol: Liver and kidney failure, low blood sugar coma may occur.
Hydrocodone may demonstrate an enhanced respiratory depressant effect when combined with other sedatives such as other opioids, benzodiazepines, nonbenzodiazepine sedatives, psychotropics, and anticonvulsants.
Laboratory function tests should be used to monitor therapy in people with severe liver or renal disease.
- Mechanism of action: Hydrocodone acts primarily as an agonist at the mu-opioid receptors, but is also a weak agonist against the delta opioid and kappa opioid receptors.
- Absorption/distribution: The oral formulation can be absorbed from the gastrointestinal tract and remain 20–50% bound to plasma proteins. The onset of analgesia is about 20 to 30 minutes with duration of 4 to 8 hours and t1/2 of 3 to 4 hours.
- Metabolism/excretion: It is metabolized to norhydrocodone by cytochrome P450 3A4 and to hydromorphone, also biologically active, by cytochrome P450 2D6. For individuals who have a defect in the gene encoding CYP2D6, the clearance of the drug will be lower and less metabolite such as hydromorphone will be formed; however, the effect on analgesia remains unknown.
- Mechanism of action: Paracetamol acts to inhibit COX enzyme, which is responsible for prostaglandin synthesis. Prostaglandins increase the perception of pain. Inhibition of prostaglandin production helps to alleviate pain.
- Absorption/distribution: The half-life of oral paracetamol is 1.25 to 3 hours and peak level is reached by 10–60 minutes after ingestion.
- Metabolism/excretion: Paracetamol is metabolized primarily in the liver via glucuronidation and sulfation to mostly non-toxic metabolites and some highly reactive metabolites, which is inactivated by glutathione. 85% of the oral dose is excreted renally. At high doses, the supply of glutathione cannot meet its demand, thus results in the accumulation of highly reactive compounds leading to liver damage.
Society and culture
In May 2017, professional golfer Tiger Woods was arrested by the police for driving under the influence. Woods said that this was due to four prescription drugs that he was taking for a back operation, one of which was Vicodin.
On 30 June 2009, a U.S. Food and Drug Administration (FDA) advisory panel voted by a narrow margin to advise the FDA to remove Vicodin and another opioid, Percocet, from the market because of "a high likelihood of overdose from prescription narcotics and acetaminophen products". The panel also cited concerns of liver damage from their paracetamol component, which is also the main ingredient in commonly used nonprescription drugs such as Tylenol. Each year, paracetamol overdose is linked to about 400 deaths and 42,000 hospitalizations.
In January 2011, the FDA asked manufacturers of prescription combination products that contain paracetamol to limit the amount of paracetamol to no more than 325 mg in each tablet or capsule within three years. The FDA also required manufacturers on all paracetamol containing products to issue a black box warning indicating the potential risk for severe liver injury and a warning highlighting potential for allergic reactions.
On 22 August 2014, the Drug Enforcement Administration (DEA) announced that all hydrocodone combination products (HCPs) will be rescheduled from Schedule III to Schedule II of the Controlled Substances Act (CSA), effective on 6 October 2014. In 2010, more than 16,000 deaths were attributed to abuse of opioid drugs. Even though there are legitimate medical uses for HCPs, data suggest that a significant number of individuals misuse them.
Vicodin is mentioned in songs such as Eminem's "Kill You", Blackbear's "Sniffing Vicodin in Paris", Kendrick Lamar's "A.D.H.D", Future's "Lay Up", Lupe Fiasco's "Mural", Queens of the Stone Age's "Feel Good Hit of the Summer", A Winged Victory for the Sullen's "Steep Hills of Vicodin Tears", Death Grips's "Anne Bonny" and The Wombats' "Give Me a Try". Vicodin use is a central theme in the 2004–2012 medical TV drama House, in which the lead character Dr. Gregory House is addicted to the drug combination.
Brand names include Adol, Hycet, Lortab, Lorcet, Norco, and Vicodin among others.
- "Hydrocodone and Acetaminophen – FDA prescribing information". Drugs.com. Retrieved 23 December 2018.
- Mancano M, Gallagher J (2010). Frequently Prescribed Medications. Jones & Bartlett Learning. p. 7. ISBN 9780763781170.
- Parrillo VN (2008). Encyclopedia of Social Problems. SAGE. p. 262. ISBN 9781412941655.
- Singla A, Sloan P (2013). "Pharmacokinetic evaluation of hydrocodone/acetaminophen for pain management". Journal of Opioid Management. 9 (1): 71–80. doi:10.5055/jom.2013.0149. PMID 23709306.
- Graham GG, Scott KF (1 February 2005). "Mechanism of action of paracetamol". American Journal of Therapeutics. 12 (1): 46–55. doi:10.1097/00045391-200501000-00008. PMID 15662292. S2CID 38261222.
- "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.
- "Acetaminophen; Hydrocodone - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.
- Atkins L (16 August 2001). "Know what a Vike is?". The Guardian. Retrieved 23 December 2018.
- "Co-codamol 30/500 Tablets - Summary of Product Characteristics (SmPC) - (eMC)". www.medicines.org.uk. Retrieved 7 August 2019.
- "Vicodin Prescribing Information for Health Care Professionals". www.vicodin.com. Retrieved 4 November 2015.
- "Acetaminophen / Hydrocodone Dosage Guide with Precautions - drugs.com". www.drugs.com. Retrieved 4 November 2015.
- "Rules – 2014 – Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II". www.deadiversion.usdoj.gov. Retrieved 4 November 2015.
- "Norco Addiction | The Fix". The Fix. 21 January 2015. Retrieved 4 November 2015.
- "Hydrocodone (Trade Names: Vicodin, Lortab, Lorcet-HD, Hycodan, Vicoprofen)" (PDF). US DOJ – DEA. April 2013. Retrieved 21 May 2013.
- "Norco – FDA prescribing information, side effects and uses". www.drugs.com. Retrieved 4 November 2015.
- Becker DE (1 January 2011). "Adverse drug interactions". Anesthesia Progress. 58 (1): 31–41. doi:10.2344/0003-3006-58.1.31. PMC 3265267. PMID 21410363.
- Vallejo R, Barkin RL, Wang VC (1 August 2011). "Pharmacology of opioids in the treatment of chronic pain syndromes". Pain Physician. 14 (4): E343-60. doi:10.36076/ppj.2011/14/E343. PMID 21785485.
- Cone EJ, Darwin WD, Gorodetzky CW, Tan T (1 August 1978). "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog". Drug Metabolism and Disposition. 6 (4): 488–93. PMID 28931.
- Kaye AD (2015). Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. Springer. pp. 134–13. ISBN 9781461489481.
- Golan DE (2008). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins. pp. 275–276. ISBN 978-0-7817-8355-2.
- Sinatra RS (2011). The Essence of Analgesia and Analgesics. Cambridge University Press. p. 256. ISBN 978-0-521-14450-6.
- "Police release dashcam footage of Tiger Woods' DUI arrest". Guardian. Associated press. 1 June 2017. Retrieved 1 June 2017.
- Murray E (29 May 2017). "Tiger Woods says medication, not alcohol led to Florida DUI arrest". Guardian. Retrieved 1 June 2017.
- "FDA advisers vote to take Vicodin, Percocet off market". CNN.
- Harris, Gardiner (13 January 2011). "F.D.A. Plans New Limits on Prescription Painkillers". The New York Times. ISSN 0362-4331. Retrieved 4 November 2015.
- "FDA limits acetaminophen in prescription combination products; requires liver toxicity warnings" (Press release). U.S. Food and Drug Administration. 13 January 2011. Retrieved 13 January 2011.
- "FDA Drug Safety Communication: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure". U.S. Food and Drug Administration (FDA). 13 January 2011. Retrieved 13 January 2011.
- Perrone M (13 January 2011). "FDA orders lowering pain reliever in Vicodin". The Boston Globe. Associated Press. Retrieved 13 January 2011.
- Harris G (13 January 2011). "F.D.A. Plans New Limits on Prescription Painkillers". The New York Times. Retrieved 13 January 2011.
- "Federal Register – Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II". usa.gov. 22 August 2014.
- "Adol (Hydrocodone-Acetaminoph) Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing – WebMD". WebMD. Retrieved 26 July 2017.
- "Acetaminophen mixture with Hydrocodone bitartrate". Drug Information Portal. U.S. National Library of Medicine.
- Vicodin U.S. Federal Regulations